Lightlake Therapeutics Inc. Announces the Appointment of International Entrepreneur Geoffrey Wolf as a Director
04 April 2011 - 5:48PM
Business Wire
Lightlake Therapeutics Inc (OTCBB:LLTP) is pleased to announce
the appointment of Geoffrey Wolf as a Director of the company.
Geoffrey Wolf is resident in both Switzerland and South Africa.
After studying for his MBA in London UK he has had a 35 year career
in international commerce and industry. This has encompassed
Minerals, Pharmaceuticals, Metals, Mining, Oil and Gas, Hospitality
and Real Estate.
As an Investor he has participated in transactions involving
Amoun, a leading Egyptian Pharmaceutical Company, and Birgi Mefar,
a major Turkish Pharmaceutical Contract Manufacturing and Services
Company.
Dr Michael Sinclair, Chairman of Lightlake Therapeutics Inc
commented: "Geoffrey Wolf brings to Lightlake a global experience
of successful entrepreneurial business. We very much look forward
to the significant contribution we are confident he will make to
our company."
Geoffrey Wolf commented: "Obesity and the associated Binge
Eating Disorder are major global healthcare challenges. Dr David
Sinclair's pioneering research into the use of Opiate Antagonists
holds great promise as a means of addressing these disorders. I
relish the opportunity to internationalize access to Lightlake's
products."
About Lightlake Therapeutics
Lightlake Therapeutics is an early stage biopharmaceutical
company aiming to build a solid platform of pharmacological
treatments based on our expertise using opioid antagonists. Other
significant developments include the use of an opioid antagonist
nasal spray to address binge-eating obesity. A Phase II trial of
this product in Helsinki is due to be completed during 2011.
This press release contains forward-looking statements. These
statements relate to future events or our future financial
performance and involve known and unknown risks, uncertainties and
other factors that may cause our or our industry's actual results,
levels of activity, performance or achievements to be materially
different from any future results, levels of activity, performance
or achievements expressed, implied or inferred by these
forward-looking statements. In some cases, you can identify
forward-looking statements by terminology such as "may," "will,"
"should," "could," "would," "expects," "plans," "intends,"
"anticipates," "believes,” estimates," "predicts," "projects,"
"potential" or "continue" or the negative of such terms and other
comparable terminology. These statements are only predictions based
on our current expectations and projections about future events.
You should not place undue reliance on these statements. Actual
events or results may differ materially. In evaluating these
statements, you should specifically consider various factors. These
and other factors may cause our actual results to differ materially
from any forward-looking statement. We undertake no obligation to
update any of the forward-looking statements after the date of this
presentation to conform those statements to reflect the occurrence
of unanticipated events, except as required by applicable law.
www.lightlaketherapeutics.com
Opiant Pharmaceuticals (NASDAQ:OPNT)
Historical Stock Chart
Von Jun 2024 bis Jul 2024
Opiant Pharmaceuticals (NASDAQ:OPNT)
Historical Stock Chart
Von Jul 2023 bis Jul 2024